TABLE 4.

Outcomes of representative clinical trials of taxanes in nonspecific STSs.

Drugs and dosages	Years of report	Study types	Setting	Number of patients	Outcomes			References
					ORR (%)	M-PFS (months)	M-OS (months)
Single agent
Docetaxel 100 mg/m2/d1/3w	2001	Phase II trial	≥2 line	27	15	2.4	7.7	Köstler et al. (2001)
Docetaxel 100 mg/m2/d1/3w	2000	Phase II trial	First-line	42	0	1.6	9.8	Verweij et al. (2000)
Docetaxel 100 mg/m2/d1/3w	1999	Phase II trial	≥2 line	36	2.8	1.4	11.7	Santoro et al. (1999)
Docetaxel 100 mg/m2/d1/3w	1998	Phase II trial	First-line	30	10.7	-	-	Bramwell et al. (1998)
Docetaxel 100 mg/m2/d1/3w	1996	Phase II trial	First-line	18	5.9	-	-	Edmonson et al. (1996)
Paclitaxel 250 mg/m2/d1/3w	1998	Phase II trial	Any-line	28	7	3.5	-	Casper et al. (1998)
Paclitaxel 200 mg/m2/d1/3w	1997	Phase II trial	≥2 line	19	0	-	-	Patel et al. (1997)
Paclitaxel 250 mg/m2/d1/3w	1995	Phase II trial	First-line	48	12.5	1.6	12	Balcerzak et al. (1995)
Combination regimens
Gemcitabine 900 mg/m2/d1,8/3w plus docetaxel 100 mg/m2/d8/3w	2021	Phase II trial	≥2 line	45	18	4.1	15.9	Somaiah et al. (2021)
Gemcitabine 900 mg/m2/d1,8/3w plus docetaxel 75 mg/m2/d8/3w	2019	Phase II trial	Any-line	70	20	5.6	21.1	Jones et al. (2019)
Gemcitabine 675 mg/m2/d1,8/3w plus docetaxel 75 mg/m2/d8/3w	2017	Phase III trial	First-line	128	20	5.5	15.7	Seddon et al. (2017)
Gemcitabine 1,000 mg/m2/d1,8/3w plus docetaxel 35 mg/m2/d1,8/3w	2012	Phase II trial	≥2 line	30	16.7	2.5	8.4	Lee et al. (2012)
Gemcitabine 900 mg/m2/d1,8/3w plus docetaxel 100 mg/m2/d8/3w	2007	Phase II trial	Any-line	73	16	6.2	17.9	Maki et al. (2007)
Pegylated liposomal doxorubicin 45 mg/m2/d1/4w plus paclitaxel 150 mg/m2/d1/4w	2004	Phase II trial	First-line	42	16	5.7	13.2	Bafaloukos et al. (2004)

STSs, soft tissue sarcomas; ORR, objective response rate; M-PFS, median progression-free survival; M-OS, median overall survival.